Lyfferon lyophilizate 1 mln.me 5 pcs

Adults as a part of complex therapy:

• acute viral hepatitis B – moderate and severe forms at the beginning of jaundice period until the 5th day of jaundice (in later periods administration of the drug is less effective;
• acute prolonged hepatitis B and C, chronic active hepatitis B and C including delta agent
• Viral (influenza, adenovirus, enterovirus, herpes, parotitis), viral-bacterial and mycoplasma meningoencephalitis. The drug is most effective in the first 4 days of the disease;
• Kidney cancer stage IV, hairy cell leukemia, malignant skin lymphoma (mycosis fungoides, primary reticulosis, rstikulosarcomatosis), Kaposi sarcoma. Basal cell and squamous cell skin cancer, keratoacanthoma. chronic myeloleukemia, Laigerhans cell histiocytosis, subleukemic myelosis, essential thrombocythemia.
• Viral conjunctivitis, keratoconjunctivitis. keratitis, keratoiridocyclitis,keratouveitis.

In case of children from 1 year old in the complex therapy:

• acute lymphoblastic leukemia in the period of remission after the end of inductive chemotherapy (for 4-5 months of remission);
• juvenile respiratory papillomatosis of the larynx, starting the day after removal of papillomas.

.

Active ingredient

Composition

Lyophilisate for preparation of solutions for intramuscular, subconjunctival injection and eye drops in the form of powder or porous mass of white, hygroscopic.

Associates:

Sodium chloride – 9.2 mg,

sodium hydrophosphate dodecahydrate (sodium phosphate disodium 12-water) – 2.74 mg,

sodium dihydrophosphate dihydrate (sodium phosphoric acid single-substituted 2-water) – 0.37 mg,

dextran with m.m. 30000 to 40000 (in the form of “Reonopolyglucin” solution containing 100 mg/1 ml of dextran in 0.9% sodium chloride solution) – 8 mg,

sorbitol (D-sorbitol) – 3 mg,

urea (urea) – 0.1 mg.

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Similarities